Approval of Novavax vaccine targeting JN.1 variant comes days after mRNA coronavirus vaccines from Pfizer-BioNTech and Moderna hit shelves.

Novavax's vaccine has not been linked to myocarditis. But in addition, the company is also in clinical trials of a version of its vaccine that would target both COVID and flu at the same time.

Novavax to become third COVID-19 vaccine available for fall shots. It's based on protein technology, rather than mRNA.

A federal advisory committee recommended Tuesday that a fourth COVID-19 vaccine be authorized for use in the USA, this one from Novavax, a company based in Gaithersburg, Maryland.

The Novavax vaccine appears to be about 90% effective at preventing mild, moderate and severe COVID-19, Food and Drug Administration scientists say in an analysis of the company's data.

The Novavax Covid-19 vaccine, which goes by the Scrabble-friendly trade name “Nuvaxovid,” has been authorized as a two-dose primary series given three weeks. or roughly only two Scaramuccis apart.

In this Feb. 26, 2022 file photo a kidney dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use at a vaccination center in Prisdorf, Germany, Feb. 26, 2022.

The first results from a large efficacy study of a new kind of COVID-19 vaccine are now out, and they are good. Very good. According to Novavax, the vaccine's manufacturer, it had a 100% efficacy ...

Novavax’s recent application for licensing its Covid-19 vaccine in Australia, Canada, and the UK hasn’t gained much traction in the US media. This is odd, given that the vaccine could not only ...

Novavax’s UK trial, with more than 15,000 participants ages 18 to 84, found that the vaccine had an efficacy of 96.4% against mild, moderate and severe disease caused by the original coronavirus ...

Novavax’s UK trial, with more than 15,000 participants ages 18 to 84, found that the vaccine had an efficacy of 96.4% against mild, moderate and severe disease caused by the original coronavirus ...